65,437 trials
Infectious Peritonitis
Primary: Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration — 40573.2; 13532.3 mg*h/L
Relatively Healthy Volunteers
Primary: Maximum Tolerance to Transcutaneous Electrical Stimulation — 27.0; 26.9 mA (milliamperes) — p=0.02
Gastrectomy · Atrial Fibrillation
Primary: Number of Disease-Specific PROMs Completed — 64; 59 # PROMs completed — p=0.04
Polymorphic Light Eruption
Primary: Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale — 0.25; 0.47 score on a scale
Active Breast Cancer Treatment
Primary: Between-group Differences in Patient Complete Illness Understanding at 9-months — 42; 38; 21; 17 Participants — p=0.264
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 9.0; 11.3; 54.0; 42.3 Percentage of Participants — p=0.175
Cerebrovascular Accident
Primary: Box & Blocks Test — 25; 36; 29; 42 blocks
Herpes Zoster
Primary: Percentage of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group — 99.1 Percentage of subjects
Indolent Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Duration of Exposure to IDELA — 8.1; 7.6; 4.2; 5.1 months
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Influenza
Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711
Postoperative Pain
Primary: Sensory Deficit (Cold Roller), Mid-axillary Line — 9.2; 9.3 cm
Retinitis Pigmentosa
Primary: Visual Field, III4e — 4835.29; 4988.43; 6234.59; 4488.39 deg2
Allergic Conjunctivitis
Primary: Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1 — 3.12; 3.02 units on a scale
Osteoporosis
Primary: If Carboxy-terminal Collagen Crosslinks (CTX) Three and Six Months After Stopping Alendronate Predicted TH BMD (Total Hip BMD) Loss Above the Least Significant Change at…